Gastric cancer and trastuzumab: First biologic therapy in gastric cancer

Krishna S. Gunturu, Yanghee Woo, Nike Beaubier, Helen E. Remotti, M. Wasif Saif*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

64 Scopus citations


Gastric cancer remains difficult to cure and has a poor overall prognosis. Chemotherapy and multimodality therapy has shown some benefit in the treatment of gastric cancer. Current therapies for gastric cancer have their limitations; thus, we are in need of newer treatment options including targeted therapies. Here, we review the biologic therapy with trastuzumab in human epidermal growth factor receptor 2 (HER2)+ gastric cancer.

Original languageEnglish (US)
Pages (from-to)143-151
Number of pages9
JournalTherapeutic Advances in Medical Oncology
Issue number2
StatePublished - Mar 2013


  • gastric cancer
  • trastuzumab

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Gastric cancer and trastuzumab: First biologic therapy in gastric cancer'. Together they form a unique fingerprint.

Cite this